Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer

被引:43
|
作者
Honselmann, Kim C. [1 ,2 ,3 ]
Pergolini, Ilaria [1 ,2 ]
Fernandez-del Castillo, Carlos [1 ,2 ]
Deshpande, Vikram [1 ,2 ]
Ting, David [2 ,4 ]
Taylor, Martin S. [1 ,2 ]
Bolm, Louisa [3 ]
Qadan, Motaz [1 ,2 ]
Wellner, Ulrich [3 ]
Sandini, Marta [1 ,2 ]
Bausch, Dirk [3 ]
Warshaw, Andrew L. [1 ,2 ]
Lillemoe, Keith D. [1 ,2 ]
Keck, Tobias [3 ]
Ferrone, Cristina R. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Gastrointestinal Surg & Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Med Ctr Schleswig Holstein, Dept Surg, Campus Luebeck, Lubeck, Germany
[4] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA
关键词
lymph node status; PDAC; recurrence; survival; SHORT-COURSE CHEMORADIATION; PROTON-BEAM THERAPY; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; NEOADJUVANT TREATMENT; PANCREATICODUODENECTOMY; CAPECITABINE;
D O I
10.1097/SLA.0000000000003123
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Our aim was to evaluate recurrence patterns of surgically resected PDAC patients with negative (pN0) or positive (pN1) lymph nodes. Summary Background Data: Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. This is mostly due to early local and distant metastasis, even after surgical resection. Knowledge about patterns of recurrence in different patient populations could offer new therapeutic avenues. Methods: Clinicopathologic data were collected for 546 patients who underwent resection of their PDAC between 2005 and 2016 from 2 tertiary university centers. Patients were divided into an upfront resection group (n = 394) and a neoadjuvant group (n = 152). Results: Tumor recurrence was significantly less common in pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%,P< 0.001 and 64% vs. 78%,P= 0.040 in the neoadjuvant group). In addition, time to recurrence was significantly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN1P< 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1,P< 0.001). Of the patients who recurred, 62% presented with distant metastases (63% of pN0 and 62% of pN1,P= 0.553), 24% with local disease (27% of pN0 and 23% of pN1,P= 0.672) and 14% with synchronous local and distant disease (10% of pN0 and 15% of pN1,P= 0.292). Similarly, there was no difference in recurrence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant metastases (76% of pN0 and 64% of pN1,P= 0.326) and 18% recurred with local disease (pN0: 22% and pN1: 15%,P= 0.435). Conclusion: Time to recurrence was significantly longer for pN0 patients. However, patterns of recurrence for pN0 vs. pN1 patients were identical. Lymph node status was predictive of time to recurrence, but not location of recurrence.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 50 条
  • [31] Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence
    Eifel, P. J.
    Klopp, A. H.
    Ramondetta, L. M.
    Gershenson, D. M.
    Jhingran, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S166 - S167
  • [32] Adjuvant chemotherapy in patients with clinically node-negative but pathologically node-positive rectal cancer in the Netherlands: A retrospective analysis
    Kwakman, Johannes J. M.
    Bond, Marinde J. G.
    Demichelis, Ramzi M.
    Koopman, Miriam
    Hompes, Roel
    Elferink, Marloes A. G.
    Punt, Cornelis J. A.
    EUROPEAN JOURNAL OF CANCER, 2024, 197
  • [33] Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer
    Davol, PA
    Bagdasaryan, R
    Elfenbein, GJ
    Maizel, AL
    Frackelton, AR
    CANCER RESEARCH, 2003, 63 (20) : 6772 - 6783
  • [34] Temporal trends and predictors in diagnosing pathologic node-positive prostate cancer in clinically node-negative patients.
    Hutten, Ryan
    Parsons, Matthew
    Weil, Christopher
    Tward, Jonathan David
    Lester-Coll, Nataniel Hernan
    Johnson, Skyler B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [35] Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer
    Veitch, Zachary
    Khan, Omar F.
    Tilley, Derek
    Ribnikar, Domek
    Kostaras, Xanthoula
    King, Karen
    Tang, Patricia
    Lupichuk, Sasha
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01): : 47 - 56
  • [36] Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients EDITORIAL COMMENT
    Daneshmand, Siamak
    UROLOGY, 2012, 80 (03) : 639 - 639
  • [37] Survival Benefit of Japanese Extended Lymphadenectomy for Clinically Node-Negative and Node-Positive Colorectal Cancers
    Ouchi, Akira
    Komori, Koji
    Kimura, Kenya
    Kinoshita, Takashi
    Shimizu, Yasuhiro
    Nagino, Masato
    DISEASES OF THE COLON & RECTUM, 2018, 61 (02) : 162 - 171
  • [38] Prognostic factors in patients with node-negative gastric carcinoma:A comparison with node-positive gastric carcinoma
    Dong Yi Kim
    Kyeung Won Seo
    Jae Kyoon Joo
    Young Kyu Park
    Seong Yeob Ryu
    Hyeong Rok Kim
    Young Jin Kim
    Shin Kon Kim
    World Journal of Gastroenterology, 2006, (08) : 1182 - 1186
  • [39] Prognostic factors in patients with node-negative gastric carcinoma: A comparison with node-positive gastric carcinoma
    Kim, Dong Yi
    Seo, Kyeung Won
    Joo, Jae Kyoon
    Park, Young Kyu
    Ryu, Seong Yeob
    Kim, Hyeong Rok
    Kim, Young Jin
    Kim, Shin Kon
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (08) : 1182 - 1186
  • [40] GREATER LYMPH NODE RETRIEVAL IMPROVES SURVIVAL IN NODE-NEGATIVE RESECTED GASTRIC CANCER
    Mirkin, Katelin
    Hollenbeak, Christopher S.
    Wong, Joyce
    GASTROENTEROLOGY, 2017, 152 (05) : S1286 - S1286